BPG is committed to discovery and dissemination of knowledge
Case Control Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123971
Published online Nov 15, 2026. doi: 10.4251/wjgo.123971
Genotype-phenotype landscape of Sodium taurocholate cotransporting polypeptide deficiency in Yunnan Province, China: A five-year retrospective, multi-ethnic cohort study
Mei-Fen Wang, Rui Chen, Zhi-Kuan Cun, Qiong Li, Department of Infectious Diseases, Affiliated Children’s Hospital of Kunming Medical University (Kunming Children’s Hospital), Kunming 650228, Yunnan Province, China
Juan Li, Department of Gastroenterology, Affiliated Children’s Hospital of Kunming Medical University (Kunming Children’s Hospital), Kunming 650228, Yunnan Province, China
Hong-Chao Jiang, Clinical Research Center, Affiliated Children’s Hospital of Kunming Medical University (Kunming Children’s Hospital), Kunming 650228, Yunnan Province, China
Ji-Wei Li, Department of Pathology, Affiliated Children’s Hospital of Kunming Medical University (Kunming Children’s Hospital), Kunming 650228, Yunnan Province, China
ORCID number: Ji-Wei Li (0000-0002-8517-9753).
Co-corresponding authors: Hong-Chao Jiang and Ji-Wei Li.
Author contributions: Wang MF, Chen R, Li J, Cun ZK and Li Q collected sample; Wang MF, Chen R, Jiang HC and Li JW performed the experiments; Wang MF, Jiang HC and Li JW wrote and revised the paper; all authors read and approved the final manuscript. Jiang HC and Li JW are designated as co-corresponding authors of this work. Both authors contributed equally to the conceptualization, study design, data interpretation, and manuscript revision. Jiang HC, as a Chief physician in the Department of Clinical Research Center, provided critical oversight of the clinical data collection and statistical analysis, and secured major funding support (Xingdian Talent Support Plan and Kunming Spring City Plan). Li JW, as a pathologist and clinical researcher, contributed substantially to the genetic data interpretation, variant classification according to ACMG/AMP guidelines, and drafting of the genotype-phenotype correlation analysis. The two co-corresponding authors collaborated closely throughout the research process and jointly supervised the project. Both have approved the final manuscript and agree to be accountable for all aspects of this work. Primary corresponding author: Li JW will serve as the single primary contact for all correspondence with the journal during submission, peer review, and publication processes. He takes primary responsibility for ensuring that all administrative requirements of the journal (including authorship details, ethics committee approval documentation, and conflict-of-interest forms) are properly completed.
AI contribution statement: No AI tools were used in the preparation of this manuscript. The authors assume full responsibility for the integrity, accuracy, and originality of all submitted materials.
Supported by The “Famous Doctor” Special Project of Xingdian Talent Support Plan of Yunnan Province, No. XDYC-YLWS-2023-0006; Kunming Spring City Plan High-Level Talent Training Project, Kunming Municipal Government “Spring City Famous Doctor” Special Project, No. C2020120231; Kunming Medical Science And Technology Leading Talent Project, No. 2022-SW (leader)-05; Kunming Medical University Affiliated Children’s Hospital Medical Technology Center for Pediatric Liver Disease Diagnosis and Treatment, No. 2024-SW(Tech)-04; Xingdian Talent Support Program for Medical and Health Talents Project, No. XDYC-YLWS-2023-0004; Technical Innovation Talent Training Target Project, No. 202305AD160058; Kunming Medical Science And Technology Academic Leading Talent Project, No. 2024-SW-14; and Research Project of the Yunnan Provincial Clinical Medicine Center, No. 2024YNLCYXZX0478.
Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki. The research protocol involving human data analysis was reviewed and approved by the Medical Ethics Committee of Kunming Children’s Hospital (Approval No. 20190211004) on 11 February 2019. The ethics committee granted approval for the analysis of existing data with informed consent conducted by means of notification.
Informed consent statement: All study participants, or their legal guardians, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Corresponding author: Ji-Wei Li, PhD, Department of Pathology, Affiliated Children’s Hospital of Kunming Medical University (Kunming Children’s Hospital), No. 288 Qianxing Street, Kunming 650228, Yunnan Province, China. km_dc_lee@163.com
Received: June 3, 2026
Revised: August 5, 2026
Accepted: September 24, 2026
Published online: November 15, 2026
Processing time: 156 Days and 1.6 Hours

Abstract
BACKGROUND

Sodium taurocholate cotransporting polypeptide deficiency (NTCPD) causes persistent hypercholanemia and neonatal cholestasis, but its genotypic and phenotypic spectrum across ethnicities and geographic backgrounds remains poorly characterized.

AIM

To characterize the genetic architecture, biochemical trajectories, and genotype-phenotype correlations of NTCPD in a multi-ethnic pediatric cohort.

METHODS

In this case cohort study, we analyzed 125 patients with genetically confirmed NTCPD from Kunming Children’s Hospital (2020-2025). Longitudinal biochemical parameters were tracked, and multivariable regression was performed to assess genotype-biochemical relationships, adjusting for age, ethnicity, and geographic location.

RESULTS

The cohort comprised 69 male and 56 female patients (83 homozygous, 25 heterozygous, and 17 compound heterozygous). The c.800C>T variant was present in all compound heterozygotes, together with 11 additional variants (four likely pathogenic variants and seven variants of uncertain significance). The cohort comprised 73 Han and 52 individuals from ethnic minority groups, predominantly Yi and Hui, distributed across 15 prefectures. Biochemical profiles indicated self-limiting hypercholanemia, with total bile acid levels declining from 178.8 ± 60.9 µmol/L (0-2 months) to 141.2 ± 77.9 µmol/L (> 4 months, P = 0.0002). Homozygous and compound heterozygous genotypes were strongly associated with hypercholanemia and vitamin E deficiency, independent of demographics. Sex-stratified analysis revealed genotype- associated elevations in aspartate aminotransferase in males and more pronounced disturbances in vitamin E and iron levels in females.

CONCLUSION

In Yunnan’s multi-ethnic population, NTCPD exhibited as self-limiting course and genetic heterogeneity across ethnic and geographic subgroups. These findings provide preliminary evidence to inform larger studies and the development of monitoring strategies.

Key Words: Sodium taurocholate cotransporting polypeptide deficiency; SLC10A1 gene; Persistent hypercholanemia; Pediatric cholestasis; Genotype-phenotype correlation

Core Tip: This 5-year retrospective study of 125 pediatric patients with sodium taurocholate cotransporting polypeptide deficiency from Yunnan Province is the largest multi-ethnic cohort to date. The results reveals that the c.800C>T founder variant predominates across 12 ethnic groups, while 11 additional variants (four likely pathogenic, seven variants of uncertain significance) contribute to allelic heterogeneity. The biochemical trajectories demonstrate self-limiting hypercholanemia with age-dependent resolution, while sex-stratified analyses uncover genotype-linked elevations in aspartate aminotransferase in males and disturbances in vitamin E and iron levels in females. These findings provide an exploratory framework for genotype-informed monitoring in ethnically diverse populations, though causality and generalizability require prospective validation.



INTRODUCTION

Neonatal cholestasis is a clinically significant condition in pediatric hepatology, with diverse causes involving complex gene-environment interactions. Within this spectrum, sodium taurocholate cotransporting polypeptide deficiency (NTCPD) is a distinct monogenic disorder of bile acid metabolism; it was first reported in humans by Vaz et al[1] and subsequently detailed in clinical case studies. Pathogenic mutations in the SLC10A1 gene impair hepatic clearance of conjugated bile salts, resulting in persistent hypercholanemia and potentially contributing to the burden of neonatal hyperbilirubinemia[2,3].

The SLC10A1 c.800C>T (p.Ser267Phe) variant is a founder mutation prevalent in East Asian populations[4-6], yet its distribution exhibits substantial geographic and ethnic heterogeneity[7,8]. Although numerous pathogenic SLC10A1 variants have been reported[9-11], the full spectrum of variants in ethnically diverse cohorts remains incomplete. Moreover, the mechanistic basis for clinical variability and the influence of genetic modifiers on disease expression await systematic investigation[12,13].

Yunnan Province in Southwest China provides a unique setting to explore the heterogeneity of NTCPD because of its substantial ethnic diversity and concentrated populations of Han Chinese and several genetically distinct ethnic minority groups[6]. Previous studies have largely overlooked this regional complexity, leaving important gaps in knowledge regarding genotype–phenotype correlations across different demographic[4,14,15]. To address these limitations, we established a retrospective, multi-ethnic pediatric cohort in Yunnan to comprehensively characterize the genetic architecture and natural history of NTCPD[16]. Using longitudinal assessments and genomic analyses, we investigated associations between SLC10A1 variants, biochemical parameters, and clinical outcomes, with particular emphasis on ethnicity and sex as potential modifiers of disease expression[13,17].

MATERIALS AND METHODS
Patient description

In this study, we enrolled 125 children with persistent hypercholanemia who presented to Kunming Children’s Hospital between January 2020 and February 2025. All inpatients routinely underwent serum total bile acid (TBA) quantification via enzymatic methods and standard liver function tests. Persistent hypercholanemia was defined according to the following criteria: (1) TBA levels exceeding five times the age-specific upper limit of normal in at least three consecutive measurements; (2) Key liver enzymes [including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)] remaining below twice the upper limit of normal; and (3) Normal serum albumin levels and coagulation function. Patients with cholestasis attributable to infectious, structural, or immunological causes were excluded. The follow-up period ranged from 0.1 months to 62 months, with 84 children completing three or more follow-up visits. Data from a prospectively maintained registry were retrospectively analyzed. The study protocol was approved by the institutional ethics committee and complied with the ethical guidelines of the Declaration of Helsinki. Written informed consent was obtained from the legal guardian of each participant.

Clinical presentations

Demographic characteristics (age, sex, weight, height), ethnic and geographic background, family history, past medical history, and clinical symptoms (jaundice, stool color, and pruritus) were recorded through interviews with the parents or caregivers. Clinicians assessed hepatosplenomegaly by palpation during physical examination.

Laboratory examination

Laboratory measurements included TBA, total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), ALT, AST, GGT, alkaline phosphatase (ALP), and alpha-fetoprotein (AFP). The levels of vitamins A, D, and E and the trace elements zinc and iron were also assessed, as was thyroid function.

Gene sequencing and variant pathogenicity prediction

A 3 mL sample of peripheral venous blood was collected from each family member. Genomic DNA was extracted using a blood genomic DNA extraction kit (Qiagen, Shanghai, China), and a genomic library was constructed using a standard library construction kit (MyGenostics, Beijing, China). All procedures were performed in strict accordance with the reagent instructions. The target region was captured by a GenCap liquid capture kit (MyGenostics, Beijing, China), and then the enriched library was sequenced using an Illumina NextSeq 500 sequencer (Illumina, CA, United States). After adapters and low-quality reads were removed, the clean reads were mapped to the reference human genome (hg19) using Burrows-Wheeler Aligner software 0.7.15. After detecting genetic variations by Genome Analysis Toolkit software 3.7, single nucleotide polymorphisms and deletions or insertions were used for annotations of the identified variations. Candidate variants were validated in family members using bidirectional Sanger sequencing. The target gene was sequenced on an ABI PRISM3730 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific). The sequencing results were compared with the corresponding reference sequences in GeneBank (www.ncbi.nlm.nih.gov) using DNASTAR software (Madison).

Statistical analysis

Comparisons among the three age groups (0-2 months, 2-4 months, and > 4 months) were performed using one-way analysis of variance (ANOVA). Bartlett’s test was used to assess the homogeneity of variances, and Brown-Forsythe and Tukey post hoc tests were performed as appropriate.

For continuous biochemical outcomes, multiple linear regression was used to evaluate the relationships between SLC10A1 gene variants and multiple biochemical parameters, including liver enzymes (ALT, AST, GGT, ALP), bilirubin fractions (TBIL, DBIL), TBA, and vitamin concentrations. All analyses were conducted in the subgroup of 84 children who completed three or more follow-up visits. The following three regression models were constructed: Model 1 was unadjusted; Model 2 was adjusted for age; and Model 3 was further adjusted for age, ethnic background, and geographic location. In all models, the normal genotype served as the reference group. The results are presented as beta coefficients with corresponding 95% confidence interval (CI). To explore potential effect modification by sex, we performed sex-stratified analyses (male = 1, female = 0) and tested for gene-sex interaction terms.

For the binary outcome of thyroid dysfunction (normal vs abnormal), binary logistic regression was applied using the same three models and covariate adjustment strategy, with results presented as odds ratio (OR) and 95%CI.

Statistical analyses were performed using SPSS (version 26.0, IBM Corp., Armonk, NY, United States). Graphical representations were generated with GraphPad Prism (version 10.0, GraphPad Software, San Diego, CA, United States). A two-sided P value < 0.05 was considered statistically significant. Given the exploratory nature of this study and the limited subgroup sample sizes, no multiple testing, such as the Bonferroni correction, was applied to the sex-stratified analyses. The results should therefore be interpreted as descriptive effect estimates rather than confirmatory evidence and require independent validation.

RESULTS
Patient characteristics

A total of 125 children with NTCPD were enrolled, including 69 males (55.2%) and 56 females (44.8%). The age of onset was predominantly early in life: 54 patients (43.2%) presented at 0-2 months, 35 (28.0%) at 2-4 months, 10 (8.0%) at 4-6 months, and 16 (12.8%) at 6-12 months. Later onset was observed in a smaller number of patients, including 3 (2.4%) at 12-24 months, 5 (4.0%) at 24-36 months, and 2 (1.6%) beyond 36 months. The mean body weight was 6.44 ± 2.46 kg (range: 1.67-14.00 kg). Thyroid function screening showed that 104 children (83.2%) were euthyroid, while 21 (16.8%) had subclinical or overt thyroid dysfunction. Genetic analysis identified homozygous SLC10A1 variants in 83 patients (66.4%), heterozygous variants in 25 (20.0%), and compound heterozygous variants in 17 (13.6%). All patients exhibited normal physical development. No cases of pruritus or steatorrhea were reported. Physical examinations revealed no significant abnormalities (Table 1 and Figure 1A-D).

Figure 1
Figure 1 Demographic, genotypic, and geographic characteristics of the sodium taurocholate cotransporting polypeptide deficiency cohort (n = 125). A: Sex comparison; B: Age group distribution; C: Comparison of thyroid function; D: Genotype profile, including homozygous, heterozygous, and compound heterozygous variants, and their distribution across Yunnan province; E: Ethnic composition of the cohort and the geographical distribution of ethnic groups within Yunnan; F: Distribution of patients from 15 distinct geographical regions and the geographical distribution of the cohort in Yunnan. aP < 0.05, bP < 0.01. M: Male; F: Female.
Table 1 Demographic and clinical characteristics of the study population.
Variable
Patient cohorts (n = 125)
Gender
    Female56
    Male69
Age of onset (months)
    0-254
    2-435
    4-610
    6-1216
    12-243
    24-365
    > 362
Weight (kg)6.44 ± 2.46 (1.67-14.00)
Thyroid function
    Normal104
    Abnormal21
Gene
    HOM83
    HET25
    Compound HET17
Ethnic group
    Han Chinese73
    China’s ethnic minorities52
    Region (Yunnan Province)
    Kunming city49
    Other regions76
Ethnic distribution

The study population consisted of 125 participants from 12 ethnic groups. The Han ethnic group was the majority (n = 73, 58.4%), and 52 participants (41.6%) belonged to ethnic minorities. The distribution was as follows: Yi (n = 17, 13.6%), Hui (n = 14, 11.2%), Dai (n = 6, 4.8%), Bai (n = 5, 4.0%), Wa (n = 2, 1.6%), Pumi (n = 2, 1.6%), and one participant each (0.8%) from the Tujia, Lahu, Blang, Mongolian, and Zhuang groups. This distribution reflects the regional ethnic diversity of Yunnan Province and the demographic predominance of the Han population (Table 1 and Figure 1E). Due to the limited sample size within each minority subgroup, these data are presented as descriptive summaries and were not subjected to formal interaction testing; they serve as a foundation for future studies designed to evaluate ethnic-specific genetic effects.

Geographical distribution

The study enrolled 125 participants from 15 prefectures in Yunnan Province. Kunming contributed the largest number of participants (n = 49, 39.2%), followed by Honghe (n = 13, 10.4%) and Zhaotong (n = 12, 9.6%). Other regions with more than five participants included Qujing (n = 10, 8.0%), Dali (n = 8, 6.4%), Yuxi (n = 6, 4.8%), Xishuangbanna (n = 6, 4.8%), and Baoshan (n = 5, 4.0%). The remaining seven prefectures had fewer participants: Wenshan and Lijiang (each n = 4, 3.2%), Pu’er (n = 3, 2.4%), Dehong (n = 2, 1.6%), and Nujiang, Chuxiong, and Lincang (each n = 1, 0.8%) (Table 1 and Figure 1F).

Age-stratified trajectory of biochemical parameters in NTCPD

Laboratory parameters were analyzed across three age strata (0-2 months, 2-4 months, and > 4 months) relative to established reference intervals (Table 2; Figures 2 and 3). TBA levels were markedly elevated, measuring 8- to 12-fold above the upper reference limit in all age groups. The highest concentrations were observed in the 0-2-month cohort (178.8 ± 60.9 µmol/L), which were significantly higher than those in the 2-month to 4-month cohort (128.5 ± 81.3 µmol/L; P = 0.0002). The levels in the > 4-month cohort were 141.2 ± 77.9 µmol/L.

Figure 2
Figure 2 Long-term changes in biochemical profiles, vitamins, and trace elements over 64 months in 84 children with ≥ 3 follow-up visits. Monitored parameters: Total bile acid, total bilirubin, indirect bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, alpha-fetoprotein, Vitamins (A, D, E), Trace elements (Zinc, Fe). TBA: Total bile acid; TBIL: Total bilirubin; IBIL: Indirect bilirubin; DBIL: Direct bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein.
Figure 3
Figure 3 Comparative analysis of parameters across age groups in 84 children with ≥ 3 follow-ups. Monitored parameters: Total bile acid, total bilirubin, indirect bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, alpha-fetoprotein, Vitamins (A, D, E), Trace elements (Zinc, Fe). TBA: Total bile acid; TBIL: Total bilirubin; IBIL: Indirect bilirubin; DBIL: Direct bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein.
Table 2 Comparison of the serum biochemical indices among the paediatric groups.
Indices
Reference ranges
Paediatric patients
P value
(0-2 months), n = 54
(2-4 months), n = 35
(> 4 months), n = 36
TBA0-15 µmol/L178.8 ± 60.87a128.54 ± 81.26b141.15 ± 77.92a vs b, P = 0.0002
TBIL0-26 µmol/L84.08 ± 67.86a43.41 ± 46.8b9.28 ± 4.22ca vs b, P = 0.0030; b vs c, P < 0.0001; a vs c, P < 0.0001
IBIL0-14 µmol/L63.49 ± 57.21a33.87 ± 44.37b5.71 ± 3.3ca vs b, P = 0.0122; b vs c, P < 0.0001; a vs c, P = 0.0004
GGT5-19 U/L128.53 ± 112.17a87.2 ± 127.38b22.57 ± 30.45ca vs c, P < 0.0001; b vs c, P = 0.0054
ALP146-500 U/L425.48 ± 157.45a343.93 ± 133.28b261.16 ± 93.14ca vs b, P = 0.0148; b vs c, P = 0.0041; a vs c, P < 0.0001
DBIL0-10 µmol/L20.74 ± 38.759.54 ± 11.284.14 ± 3.35NS
ALT7-30 U/L37.50 ± 29.9542.44 ± 48.9540.69 ± 39.15NS
AST14-44 U/L64.24 ± 54.8164.44 ± 54.0956.17 ± 22.54NS
AFP< 200 µg/L5472.47 ± 12515.01515.87 ± 2992.8172.72 ± 183.27NS
Vit A1.05-2.8 µmol/L 1.467 ± 0.551.79 ± 0.732.00 ± 0.58NS
Vit D50-147 nmol/L79.60 ± 34.7197.75 ± 37.55122.52 ± 35.44NS
Vit E16.25-33.5 µmol/L26.25 ± 8.1929.0 ± 7.0129.23 ± 7.14NS
Zinc3.7-7.3 mg/L3.91 ± 0.593.47 ± 0.94.33 ± 0.49NS
Fe373.5-557.2 mg/L399.35 ± 30.26631.93 ± 890.43409.24 ± 32.72NS

Both conjugated and unconjugated hyperbilirubinemia demonstrated a similar pattern of decline with age. TBIL decreased from 84.1 ± 67.9 µmol/L in the 0-month to 2-month group to 9.3 ± 4.2 µmol/L in the > 4-month group (P < 0.0001), while IBIL decreased from 63.5 ± 57.2 µmol/L to 5.7 ± 3.3 µmol/L (P < 0.0001). DBIL also exhibited a downward trend, though this did not reach statistical significance.

Cholestatic indices followed a comparable pattern, with GGT activity peaking during early infancy (128.5 ± 112.2 U/L) and declining significantly in the > 4-month group (22.6 ± 30.5 U/L; P = 0.005). ALP levels decreased from 425.5 ± 157.5 U/L to 261.2 ± 93.1 U/L (P < 0.0001).

In contrast, markers of hepatocellular injury remained mild and age-stable. ALT and AST were only modestly elevated and showed no significant intergroup differences. AFP was substantially elevated in the youngest cohort (5472 ± 12515 µg/L) but declined to near-normal levels thereafter (72.7 ± 183 µg/L).

The nutritional parameters generally improved with age. Vitamin D concentrations increased from 79.6 ± 34.7 nmol/L to 122.5 ± 35.4 nmol/L, while vitamins A and E remained within reference ranges. Zinc and iron levels were largely normal across groups, with only minor, non-significant variations observed.

In summary, NTCPD presents as a self-limiting, age-modulated cholestatic disorder characterized by prominent early hypercholanemia, elevated GGT and AFP levels, but minimal evidence of hepatocellular injury and generally preserved nutritional status.

Genetic spectrum and variant characterization of SLC10A1

Genetic profiling of 125 pediatric patients with NTCPD revealed three distinct genotypic patterns: 83 cases (66.4%) carried homozygous SLC10A1 variants; 25 (20.0%) were heterozygous, and 17 (13.6%) were compound heterozygous. Comprehensive analysis of the 17 compound heterozygous probands and their families identified 11 distinct SLC10A1 variants. The c.800C>T (p.Ser267Phe) variant was present in all compound heterozygous cases as one allele.

Parental genotyping demonstrated that 15 of the 17 cases followed a classical autosomal recessive inheritance pattern, where the c.800C>T variant was inherited from one parent and the secondary variant was inherited from the other parent. However, two cases (probands 1 and 10) showed atypical inheritance patterns, with both maternal variants residing in cis. In proband 1, the mother carried both the c.800C>T and c.185C>T variants on the same allele, while in proband 10, the mother carried both the c.800C>T and c.402G>A variants similarly in cis.

According to ACMG/AMP guidelines, four variants were classified as likely pathogenic (LP): C.682_683del, c.263T>C (identified in three families); c.54delT (found in three families); and c.54del. The remaining seven variants were categorized as variants of uncertain significance (VUS) and included the following: C.185C>T, c.944-32G>C (observed in three families); c.799T>C, c.402G>A, c.422dupA (detected in two families); c.997G>A (identified in two families); and c.413T>C. This genetic landscape highlights both the predominance of the c.800C>T founder variant and the substantial allelic heterogeneity underlying NTCPD in this cohort (Tables 1 and 3; Figures 1D and 4).

Figure 4
Figure 4 Analysis of the 17 compound heterozygous probands and their families identified a total of 11 distinct SLC10A1 variants.
Table 3 Spectrum of homozygous, heterozygous, and compound heterozygous variants in 125 affected individuals.

Father
Mother
ACMG classification
Proband (n = 17)Compound heterozygous
c.800C>T, c.185C>Tc.800C>Tc.800C>T, c.185C>Tc.185C>T: VUS
c.800C>T, c.944-32G>Cc.944-32G>Cc.800C>Tc.944-32G>C: VUS
c.800C>T, c.944-32G>Cc.800C>Tc.944-32G>Cc.944-32G>C: VUS
c.800C>T, c.263T>Cc.263T>Cc.800C>Tc.944-32G>C: VUS
c.800C>T, c.682_683delc.682_683delc.800C>Tc.682_683del: LP
c.799T>C, c.800C>Tc.800C>Tc.799T>Cc.799T>C: VUS
c.800C>T, c.263T>Cc.800C>Tc.263T>Cc.263T>C: P
c.800C>T, c.54delTc.800C>T c.54delTc.54delT: LP
c.800C>T, c.54delTc.800C>Tc.54delTc.54delT: LP
c.800C>T, c.402G>Ac.800C>Tc.800C>T, c.402G>Ac.402G>A: VUS
c.422dupA, c.800C>Tc.800C>Tc.422dupAc.422dupA: VUS
c.422dupA, c.800C>Tc.800C>Tc.422dupAc.422dupA: VUS
c.997G>A, c.800C>Tc.997G>A, c.800C>Tc.800C>Tc.997G>A: VUS
c.997G>A, c.800C>Tc.997G>A, c.800C>Tc.800C>Tc.997G>A: VUS
c.800C>T, c.54delc.54delc.800C>Tc.54del: LP
c.800C>T, c.263T>Cc.800C>Tc.263T>Cc.263T>C: P
c.800C>T, c.413T>Cc.800C>T, c.413T>Cc.800C>Tc.413T>C: VUS
Proband (n = 25)Heterozygous
c.800C>Tc.800C>Tc.800C>T: P
c.800C>Tc.800C>T
c.263T>Cc.263T>Cc.263T>C: P
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.745C>Tc.745C>Tc.745C>T: VUS
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
c.800C>Tc.800C>T
Proband (n = 83)homozygous
c.800C>Tc.800C>Tc.800C>Tc.800C>T: P
Genetic classification and clinical attribution

Based on the ACMG/AMP variant classification and the observed genotype–phenotype associations in this cohort, we propose the following clinical attribution framework for SLC10A1-related phenotypes: (1) Classical NTCPD (homozygous or compound heterozygous). Patients with biallelic SLC10A1 variants (homozygous or compound heterozygous) were assigned to the classical NTCPD group. This category included 83 homozygotes, all carrying c.800C>T in the homozygous state, and 17 compound heterozygotes. In our regression models, this group corresponds to Gene 1 (HOM) and Gene 3 (Compound HET); and (2) NTCPD associated hypercholanemia (heterozygous or monoallelic). The 25 heterozygous patients (all c.800C>T carriers) were classified as having NTCPD associated hypercholanemia or a monoallelic phenotype. This term highlights their clinical presentation and persistent hypercholanemia according to our enrollment criteria, rather than adherence to a recessive Mendelian framework.

Several factors support including these heterozygotes. First, all met the phenotype-driven entry criteria. Second, during infancy, when the bile acid load is high and hepatic transporter reserve may be limited, a single defective allele could still impair bile acid clearance. Third, our targeted sequencing cannot rule out a second variant in noncoding regions. Fourth, the cis-acting variants observed in two probands suggest that allelic configuration may influence expressivity in some families. In the regression analyses, this group is designated as Gene 2 (HET) and was evaluated separately to reflect the broader clinical spectrum of SLC10A1 related hypercholanemia.

Associations between gene variants and serum biochemical parameters

Multivariable-adjusted analyses of the relationships between gene variants and serum biochemical indices in the 84 pediatric participants are presented in Table 4. Three sequential regression models were constructed: A crude model (Model 1), a model adjusted for age (Model 2), and a fully adjusted model that additionally accounted for age, ethnicity, and geographic location (Model 3).

Table 4 Multivariable-adjusted associations between gene variants and serum biochemical indices in 84 pediatric participants.

Model 1
Model 2
Model 3
Characteristic
Beta
95%CI
P value
Beta
95%CI
P value
Beta
95%CI
P value
GeneTBA
18231-1320.0028331-1340.0028626-1470.007
2-2.0-58 to 54> 0.9-2.1-59 to 55> 0.9-6.1-72 to 600.9
39536-1550.0029535-1550.0039523-1660.011
GGT
1-182-284 to -80< 0.001-176-279 to -730.001-253-380 to -125< 0.001
2-189-302 to -760.002-189-303 to -760.002-255-394 to -116< 0.001
3-149-269 to -290.017-149-270 to -290.017-244-393 to -950.002
AFP
1800-4142 to 57410.81294-3717 to 63050.6490-7846 to 8826> 0.9
2-441-5886 to 50040.9-447-5883 to 49880.9-1149-9866 to 75680.8
36,416207-126240.0486349150-125470.0505334-350 to 146190.3
Vit D
1-24-56 to 7.60.14-27-59 to 5.10.10-18-55 to 190.4
2-4.1-40 to 320.8-4.0-39 to 320.8-0.91-41 to 40> 0.9
3-43-81 to -3.70.035-42-81 to -3.80.035-35-80 to 100.13
Vit E
1-13-19 to -7.5< 0.001-13-19 to -7.4< 0.001-15-22 to -8.1< 0.001
2-7.8-14 to -1.50.018-7.8-14 to -1.40.019-9.3-17 to -1.90.017
3-14-23 to -6.10.001-14-23 to -6.00.001-16-25 to -6.60.002

TBA: Gene variants 1 and 3 were consistently associated with elevated TBA levels across all models. In Model 3, variant 1 was associated with an increase of 86 units (95%CI: 26-147; P = 0.007); variant 3 with an increase of 95 units (95%CI: 23-166; P = 0.011); and variant 2 was not significantly associated with TBA in any model (Model 3: Β = -6.1, 95%CI: -72 to 60; P = 0.9).

GGT: All three gene variants showed significant inverse associations with GGT levels; these associations remained consistent and were strengthened in Model 3. Specifically, in Model 3, variant 1 was associated with a reduction of 253 units (95%CI: -380 to -125; P < 0.001), variant 2 with a reduction of 255 units (95%CI: -394 to -116; P < 0.001), and variant 3 with a reduction of 244 units (95%CI: -393 to -95; P = 0.002).

AFP: A significant positive association was observed between variant 3 and AFP levels in Model 1 (β = 6,416, 95%CI: 207-12624; P = 0.048) and Model 2 (β = 6349, 95%CI: 150-12547; P = 0.050). However, this association was attenuated and lost statistical significance in Model 3 (β = 5334, 95%CI: –3950 to 14619; P = 0.3). No significant associations were found between variants 1 or 2 and AFP in any model.

Vitamin D: Variant 3 was significantly associated with lower vitamin D levels in Model 1 (β = -43, 95%CI: -81 to -3.7; P = 0.035) and Model 2 (β = –42, 95%CI: -81 to -3.8; P = 0.035). However, this association was not sustained in Model 3 (β = -35, 95%CI: -80 to 10; P = 0.13). Variants 1 and 2 did not show any significant association with vitamin D levels.

Vitamin E: All three gene variants were consistently associated with lower vitamin E levels across all models. In Model 3, variant 1 was associated with a decrease of 15 units (95%CI: -22 to -8.1; P < 0.001), variant 2 with a decrease of 9.3 units (95%CI: -17 to -1.9; P = 0.017), and variant 3 with a decrease of 16 units (95%CI: -25 to -6.6; P = 0.002).

Associations between gene variants and thyroid dysfunction

Logistic regression analyses were performed to examine the relationships between gene variants and thyroid dysfunction in the pediatric cohort, with the results detailed in Table 5. Three models were constructed: An unadjusted model (Model 1), a model adjusted for sex (Model 2), and a fully adjusted model that included sex, age, ethnicity, and location (Model 3). In Model 1, gene variant 1 demonstrated a significant inverse association with thyroid dysfunction (OR = 0.07, 95%CI: 0.01-0.42, P = 0.006). This association remained significant after adjusting for sex in Model 2 (OR = 0.07, 95%CI: 0.01-0.45, P = 0.007). However, following full adjustment for covariates in Model 3, the association was attenuated and no longer statistically significant (OR = 0.14, 95%CI: 0.01-1.58, P = 0.12). Gene variant 2 was not significantly associated with thyroid dysfunction in any of the models. In Model 1, the OR was 0.17 (95%CI: 0.02-1.18, P = 0.085); in Model 2, the OR was 0.17 (95%CI: 0.02-1.33, P = 0.10); and in Model 3, the OR was 0.42 (95%CI: 0.03-5.62, P = 0.5). A similar pattern was observed for gene variant 3, which showed a non-significant trend toward a reduced risk of thyroid dysfunction in both Model 1 (OR = 0.11, 95%CI: 0.01-0.96, P = 0.060) and Model 2 (OR = 0.11, 95%CI: 0.01-0.96, P = 0.060). This association also lost significance in Model 3 (OR = 0.40, 95%CI: 0.02-6.60, P = 0.5).

Table 5 Logistic-regression associations between gene variants and thyroid dysfunction in 84 pediatric participants.

Model 1
Model 2
Model 3
Characteristic
OR
95%CI
P value
OR
95%CI
P value
OR
95%CI
P value
Gene
10.070.01-0.420.0060.070.01-0.450.0070.140.01-1.580.12
20.170.02-1.180.0850.170.02-1.330.100.420.03-5.620.5
30.110.01-0.960.0600.110.01-0.960.0600.400.02-6.600.5
Sex-stratified analysis in male pediatric participants

Sex-stratified multivariable linear regression analysis was performed to examine associations between genotypes and serum biochemical indices in male pediatric participants (n = 41), with results presented in Table 6. Three models were constructed: An unadjusted model (Model 1), a model adjusted for age (Model 2), and a fully adjusted model that included age, ethnicity, and location (Model 3).

Table 6 Sex-stratified multivariable linear regression: Associations between genotypes and serum biochemical indices in male pediatric participants.

Model 1
Model 2
Model 3
Characteristic
Beta
95%CI
P value
Beta
95%CI
P value
Beta
95%CI
P value
GeneTBA
11083.1-2140.0511092.2-2160.05320669-3420.007
230-78 to 1380.629-80 to 1390.6105-37 to 2460.2
392-28 to 2110.1491-30 to 2120.1517626-3260.031
AST
118-6.0 to 420.218-6.1 to 430.25528-82< 0.001
217-7.7 to 420.217-8.2 to 420.25122-790.002
314-14 to 410.313-14 to 410.34919-790.004
ALP
1-317-484 to -150< 0.001-305-463 to -148< 0.001-349-611 to -870.016
2-262-433 to -900.005-271-433 to -1090.002-293-565 to -210.046
3-354-544 to -165< 0.001-359-538 to -181< 0.001-375-662 to -870.018
Vit A
10.40-0.59 to 1.40.40.34-0.61 to 1.30.50.12-1.2 to 1.50.9
20.28-0.73 to 1.30.60.32-0.65 to 1.30.50.40-1.0 to 1.80.6
31.10.00-2.20.0601.10.07-2.20.0460.94-0.55 to 2.40.2

TBA: In Model 3, genotype 1 was significantly associated with increased TBA levels (β = 206, 95%CI: 69-342, P = 0.007). Genotype 3 also showed a significant positive association with TBA in Model 3 (β = 176, 95%CI: 26-326, P = 0.031). No significant associations were observed between genotype 2 and TBA levels across any models.

AST: All three genotypes demonstrated significant positive associations with AST levels in the fully adjusted model. Specifically, genotype 1 was associated with an increase in AST (β = 55, 95%CI: 28-82, P < 0.001), as were genotype 2 (β = 51, 95%CI: 22-79, P = 0.002) and genotype 3 (β = 49, 95%CI: 19-79, P = 0.004). No significant associations were observed in the less adjusted models.

ALP: All genotypes showed consistent inverse associations with ALP levels across all models. In Model 3, genotype 1 was associated with a reduction in ALP (β = 349, 95%CI: 611-87, P = 0.016), along with genotype 2 (β = 293, 95%CI: 565-21, P = 0.046) and genotype 3 (β = 375, 95%CI: 662-87, P = 0.018).

Vitamin A: A marginally significant positive association was observed between genotype 3 and vitamin A levels in Model 2 (β = 1.1, 95%CI: 0.07-2.2, P = 0.046). However, this association was not maintained in Model 3. No significant associations were found between other genotypes and vitamin A levels in any model.

Sex-stratified analysis in female pediatric participants

Associations between genotypes and serum biochemical parameters in female participants (n = 43) were examined using sex-stratified multivariable linear regression analysis, with the results summarized in Table 7. Three models were constructed: An unadjusted model (Model 1), a model adjusted for age (Model 2), and a fully adjusted model that included age, ethnicity, and location (Model 3).

Table 7 Sex-stratified multivariable linear regression: Associations between genotypes and serum biochemical indices in female pediatric participants.

Model 1
Model 2
Model 3
Characteristic
Beta
95%CI
P value
Beta
95%CI
P value
Beta
95%CI
P value
GeneTBA
18928-1500.0078927-1520.00876-8.3 to 1600.089
213-65 to 920.713-67 to 930.7-1.9-96 to 92> 0.9
310433-1750.00710432-1760.007970.44-1940.059
GGT
1-215-373 to -560.012-210-372 to -480.015-346-565 to -1280.004
2-223-428 to -190.039-223-431 to -160.041-307-551 to -640.020
3-172-357 to 130.076-172-359 to 150.079-327-578 to -760.016
AFP
11589-6335 to 95130.72004-6132 to 101400.6-1748-16919 to 134220.8
2-273-10648 to 10102> 0.9-253-10761 to 10255> 0.9-1385-17234 to 144630.9
311291916-216660.04311147629-216650.0499749-6415 to 259140.3
Vit D
1-34-70 to 2.30.075-33-70 to 4.30.092-5.9-50 to 380.8
2-9.3-56 to 370.7-9.3-56 to 380.7-0.01-49 to 49> 0.9
3-66-110 to -210.007-66-111 to -210.007-34-88 to 190.2
Vit E
1-15-23 to -7.5< 0.001-15-24 to -7.20.001-22-34 to -100.003
2-8.8-19 to 1.20.10-8.8-19 to 1.40.10-11-22 to -0.480.060
3-18-35 to -0.720.052-18-36 to -0.370.056-23-42 to -4.80.027
Fe
1-34-58 to -8.90.018-36-62 to -110.015-58-100 to -150.032
2-36-68 to -3.80.045-36-69 to -3.70.047-44-84 to -4.00.068
3-25-72 to 220.3-25-73 to 220.3-48-106 to 9.40.15
Thyroid dysfunction
10.060.00-0.550.0170.080.01-0.710.0300.230.01-5.140.3
21.000.07-13.8> 0.91.000.07-14.0> 0.91.570.08-41.50.8
30.100.00-1.200.0940.170.01-2.430.20.450.01-16.00.7

TBA: Genotype 1 was positively associated with TBA in Models 1 (β = 89, 95%CI: 28-150, P = 0.007) and 2 (β = 89, 95%CI: 27-152, P = 0.008), but not in Model 3 (β = 76, 95%CI: -8.3 to 160, P = 0.089). Genotype 3 was significantly associated with TBA in Models 1 and 2 (β = 104, P = 0.007 for both), with a borderline association in Model 3 (β = 97, 95%CI: 0.44-194, P = 0.059). Genotype 2 was not associated with TBA in any model.

GGT: All genotypes were inversely associated with GGT levels in Model 3: Genotype 1 (β = -346, 95%CI: –565 to -128, P = 0.004), genotype 2 (β = –307, 95%CI: -551 to -64, P = 0.020), and genotype 3 (β = -327, 95%CI: -578 to -76, P = 0.016).

AFP: Genotype 3 was positively associated with AFP in Models 1 (β = 11291, 95%CI: 916-21666, P = 0.043) and 2 (β = 11147, 95%CI: 629-21665, P = 0.049), but not in Model 3 (β = 9749, 95%CI: -6415 to 25914, P = 0.3). Genotypes 1 and 2 showed no significant associations.

Vitamin D: Genotype 3 was inversely associated with vitamin D in Models 1 and 2 (β = –66, P = 0.007 for both), but not in Model 3 (β = -34, 95%CI: -88 to 19, P = 0.2). Genotype 1 showed a trend in Models 1 and 2, which was attenuated in Model 3. Genotype 2 was not associated with vitamin D in any model.

Vitamin E: Genotypes 1 and 3 were significantly inversely associated with vitamin E in Model 3 (β = -22, 95%CI: -34 to -10, P = 0.003 and β = -23, 95%CI: -42 to -4.8, P = 0.027, respectively). Genotype 2 showed a marginal association in Model 3 (β = -11, 95%CI: -22 to -0.48, P = 0.060).

Iron: Genotype 1 was inversely associated with iron in all models, including Model 3 (β = -58, 95%CI: -100 to -15, P = 0.032). Genotype 2 showed a similar trend in Model 3 (β = -44, 95%CI: -84 to -4.0, P = 0.068). Genotype 3 was not associated with iron levels.

Thyroid dysfunction

Within the female subgroup, genotype 1 was inversely associated with thyroid dysfunction in Model 1 (OR = 0.06, 95%CI: 0.00-0.55, P = 0.017) and 2 (OR = 0.08, 95%CI: 0.01-0.71, P = 0.030), but not in Model 3 (OR = 0.23, 95%CI: 0.01-5.14, P = 0.3). Genotype 3 showed a marginal association only in Model 1 (OR = 0.10, 95%CI: 0.00-1.20, P = 0.094).

DISCUSSION

Based on the comprehensive findings from this 5-year retrospective multi-ethnic cohort study, we delineate the complex genotype-phenotype landscape of NTCPD in Yunnan Province, China. Our analysis reveals several critical dimensions of this disorder. Given the rarity of NTCPD, this study should be considered exploratory rather than confirmatory in nature. Our objective was not to provide definitive clinical guidance, but to map the preliminary landscape of this disorder in a genetically diverse population, thereby generating testable hypotheses for subsequent investigations.

The cohort demonstrated notable demographic variations, with a male predominance (55.2%) and early infancy presentation (43.2% within 0-2 months). Thyroid dysfunction was observed in 16.8% of participants, while genetic analysis identified three distinct patterns: Homozygous (66.4%), heterozygous (20.0%), and compound heterozygous (13.6%) variants. The ethnic composition reflected Yunnan’s exceptional diversity, with 41.6% belonging to minority groups, predominantly Yi (13.6%), Hui (11.2%), Dai (5.0%), and Bai (4.1%). This ethnic distribution closely corresponded with geographical patterns, where cases from minority-concentrated prefectures aligned with traditional autonomous regions[8,15]. The widespread distribution across multiple prefectures with high ethnic minority densities suggests a correlation between the distribution of NTCPD cases and regional ethnic concentrations, likely reflecting underlying population-specific genetic susceptibilities[18-20].

Analysis across age strata revealed a dynamic biochemical progression that delineates the natural course of NTCPD. Cholestatic parameters demonstrated a particularly prominent age-dependent resolution. TBA levels peaked dramatically in the 0-2 months cohort before declining significantly. Parallel changes were observed in bilirubin metabolism, with both total and IBIL decreasing precipitously from markedly elevated neonatal levels to near-normal ranges beyond 4 months. GGT activity followed a similar trajectory, showing substantial elevation during early infancy but normalizing significantly after 4 months of age.

In contrast to these evolving cholestatic markers, indicators of hepatocellular injury remained essentially stable. Both ALT and AST maintained only modest elevations without significant intergroup differences, reinforcing the non-progressive nature of the condition[21]. The age-dependent decline in AFP paralleled normal physiological liver maturation, and was therefore not interpreted as a disease-specific phenomenon[22,23].

The nutritional parameters generally demonstrated favorable profiles. The vitamin D concentrations increased significantly with advancing age (from 79.6 nmol/L ± 34.7 nmol/L to 122.5 nmol/L ± 35.4 nmol/L), while vitamins A and E, along with zinc and iron levels, remained largely within reference ranges throughout infancy. This pattern suggests that most nutritional biomarkers remained within age-appropriate reference ranges, suggesting that clinically significant malabsorption was not evident in this cohort despite the underlying transporter defect[24,25]. It is important to note that despite the significant associations observed for vitamin E and iron, the absolute levels for most nutritional parameters remained within or near reference ranges. Thus, these findings should not be interpreted as evidence of generalized malabsorption or nutritional failure in NTCPD; rather, they represent biochemical correlates that require prospective evaluation before any clinical action is warranted. Collectively, these age-stratified biochemical patterns characterize NTCPD as a self-limiting cholestatic disorder with prominent early manifestations that progressively ameliorate during infancy[10,26]. The preserved liver function and adequate nutritional status therefore support a conservative management strategy focused on monitoring over aggressive intervention[17,26].

Comprehensive genotypic analysis revealed a distribution pattern where homozygous variants predominated (66.4%), consistent with characteristic autosomal recessive inheritance[1,6]. However, the substantial proportion of heterozygous cases (20.0%) presents intriguing clinical implications, as these patients may harbor undetected secondary variants or demonstrate modifying influences from other genetic or environmental factors[27,28]. The compound heterozygous subgroup (13.6%) proved particularly informative for understanding allelic heterogeneity[11]. The c.800C>T variant was invariably present in all compound heterozygous cases, confirming its established role as the primary founder mutation in East Asian populations[5,6]. Partnered with this common variant, we identified 11 distinct secondary mutations, demonstrating remarkable mutational diversity[9,11]. According to ACMG classification standards[29,30], four variants were categorized as LP, providing clear guidance for genetic counseling and prenatal diagnosis[31]. The remaining seven VUS pose a clinical challenge yet offer potential insights into novel disease mechanisms[28]. The seven VUS variants identified in this study (c.185C T, c.944-32G>C, c.799T>C, c.402G>A, c.422dupA, c.997G>A, c.413T>C) currently lack functional validation. However, their segregation patterns within affected families provide important supportive evidence: (1) c.944-32G>C was observed in trans with c.800C>T in three independent families, with all affected members exhibiting hypercholanemia; (2) c.422dupA was recurrent in two families, consistently co-segregating with the phenotype; and (3) c.997G>A showed a similar pattern in two pedigrees. While these variants do not yet meet the ACMG criteria for “pathogenic”, the recurrent family-based co-segregation significantly strengthens their clinical relevance. Functional validation through in vitro bile acid transport assays or iPSC-derived hepatocyte models is warranted to confirm pathogenicity. Parental genotyping unequivocally confirmed autosomal recessive inheritance patterns across all families, excluding de novo mutations and establishing a 25% recurrence risk for affected families[9,22]. These genetic findings substantially advance our understanding of NTCPD. While c.800C>T remains the predominant mutation, the expanded mutational spectrum underscores the necessity for comprehensive SLC10A1 gene sequencing rather than targeted mutation analysis, particularly in genetically diverse regions[8,14]. The identified variants provide valuable targets for functional studies and future investigations into genotype phenotype correlations.

To delineate genotype-phenotype relationships while accounting for potential confounders, we employed sequential multivariable regression models with increasing stringency. This analytical approach revealed distinct patterns of association across biochemical parameters. Notably, homozygous and compound heterozygous variants demonstrated robust positive associations with TBA levels that persisted across all models. In the fully adjusted model, the effect estimates remained stable or even strengthened indicating that these genotype effects are independent of major demographic confounders. In contrast, heterozygous variants showed no significant association with TBA in any model, supporting the classic autosomal recessive inheritance pattern of NTCPD[1,21]. Moreover, a paradoxical inverse relationship emerged for GGT, with all genotypes showing consistent negative associations that intensified following full adjustment for demographic variables. This pattern suggests the presence of competing factors that may partially mask the genuine genetic effect on GGT regulation in NTCPD[16,18]. Vitamin E metabolism exhibited another robust association, with all genotypic groups demonstrating significantly lower levels across all models. The persistence of this relationship after comprehensive adjustment indicates an association between SLC10A1 genotypes and lower serum vitamin E levels, extending even to heterozygous carriers, although the clinical significance of this remains uncertain[1,24,25]. However, several initially observed associations proved susceptible to demographic confounding. Apparent relationships between compound heterozygous variants and both AFP and vitamin D levels attenuated to non-significance after full adjustment. Similarly, the initially observed inverse association with thyroid dysfunction disappeared upon controlling for demographic factors, indicating these were likely spurious associations driven by ethnic or geographic clustering rather than direct genetic effects.

These findings highlight several key insights. The core biochemical hallmarks of NTCPD, consisting of elevated TBA and reduced vitamin E levels, maintain genuine genetic associations that are not influenced by demographic factors[1,10,12]. The relationship observed with GGT reveals a complex regulatory mechanism that may be unique to NTCPD among cholestatic disorders[18,20]. Furthermore, our results emphasize the need for comprehensive adjustment of demographic variables in genetic association studies, particularly in ethnically diverse populations[8,12,13].

First, regarding the TBA-genotype link, the NTCP protein, encoded by SLC10A1, mediates sodium-dependent uptake of conjugated bile acids into hepatocytes. The c.800C>T (p.Ser267Phe) alteration lies within the transmembrane region and has been shown to reduce transport activity by 40%-70% in functional assays[32,33]. In homozygotes, this severe functional loss impairs the hepatic clearance of bile acids returning via the enterohepatic circulation, leading to hypercholanemia. The graded effect observed across genotype groups (homozygotes showing the highest TBA levels, followed by compound heterozygotes, then heterozygotes) is consistent with this dose dependent model.

Second, in terms of the possible explanations for sex related differences, several mechanisms could account for the sex stratified patterns we observed, although all remain speculative. These include estrogen mediated regulation of bile acid transporters, as animal studies have shown that estrogen can downregulate NTCP and OATP expression, although our prepubertal cohort limits direct extrapolation. X chromosome linked genes involved in bile acid metabolism may also contribute to baseline expression differences between males and females. Additionally, hepatic developmental trajectories, including the maturation of drug metabolizing enzymes, are known to follow sex dependent patterns in infancy, and similar processes may influence bile acid transport systems; however, functional studies are needed to clarify these possibilities.

Third, regarding the potential basis for the vitamin E findings, vitamin E is a lipid soluble nutrient whose absorption relies on intact bile acid mediated micelle formation. Altered bile acid composition resulting from NTCP deficiency could interfere with this process and reduce vitamin E uptake efficiency. The iron association is less straightforward but may involve shared regulatory pathways between bile acid metabolism and iron homeostasis, such as the hepcidin-ferroportin axis. However, this connection remains poorly understood and requires further investigation.

Our sex-stratified analysis uncovered fundamental differences in how genetic variants manifest biochemically between male and female pediatric patients. Sex emerged as a potential effect modifier in our regression models; however, this observation requires independent validation in NTCPD, revealing distinct pathophysiological pathways.

In male patients, the most significant associations emerged specifically in the fully adjusted model, suggesting that demographic factors substantially confound genotype-phenotype relationships in this group. The association between homozygous and compound heterozygous variants with TBA levels became highly significant in the fully adjusted model with substantially larger effect sizes. This pattern indicates that the genetic contribution to TBA elevation in males becomes fully apparent only after accounting for demographic confounders. More importantly, all three genotypes demonstrated highly significant positive associations with AST levels exclusively in the fully adjusted model. This represents a crucial finding, as AST remained stable in female patients, suggesting that the association between genotypes and AST levels was more pronounced in male patients in our adjusted models[13,21,25].

Female patients exhibited a distinct pattern: While associations were often apparent in less stringent models, they showed particular vulnerability in nutritional parameters. Notably, the TBA associations observed in initial models attenuated after full adjustment. However, female patients demonstrated more highly significant differences in serum vitamin E and iron levels. Both homozygous and compound heterozygous variants showed significant inverse associations with vitamin E levels in the fully adjusted model, with effect sizes exceeding those in males. Furthermore, homozygous variants exhibited consistent inverse associations with iron levels across all models; the inverse genotype-iron association reached statistical significance only in female patients, a finding that merits further mechanistic investigation.

These sex-stratified findings have important clinical implications. For male patients, our findings support the hypothesis that male patients may warrant closer biochemical surveillance; however, this recommendation requires prospective validation, including assessment of whether controlling hypercholanemia improves outcomes[13,20,34]. In contrast, the associations observed in female patients suggest that nutritional parameters deserve further investigation in future studies, particularly vitamin E and iron levels[16,35]. From a pathophysiological perspective, these observations raise important questions regarding the mechanisms underlying sexual dimorphism in NTCPD[36]. These observations highlight key unresolved questions, particularly the basis for greater hepatocellular susceptibility in males and the specific iron metabolism disturbances in females. These distinct patterns provide compelling directions for future investigations into potential hormonal influences, sex-specific gene expression, or other biological mechanisms governing these differences[25,37].

While providing valuable insights into NTCPD, our study has several limitations that should be considered when interpreting the results and designing future research. The present cohort, while substantial for a rare disorder, presents limitations in subgroup analyses, particularly when examining compound heterozygous cases across multiple strata. This restriction reduces statistical power for detecting genuine differences and limits deeper genotype-phenotype correlation analyses. Furthermore, the exclusive focus on Yunnan Province may limit generalizability to other populations with different demographic characteristics. Although the ethnic diversity of our cohort is a unique strength, the small sizes of individual minority groups preclude robust statistical inference regarding ethnicity as an independent modifier of genotype-phenotype relationships. Moreover, the observed geographic clustering of cases in minority-concentrated prefectures is intriguing but remains hypothesis-generating. Larger, multicenter collaborative studies are needed to disentangle genetic from environmental contributions to phenotypic variation in NTCPD. Furthermore, the observational nature of our study design inherently restricts causal inference. Although we demonstrate strong associations between genotypes and biochemical phenotypes, definitive proof of causality requires functional validation through experimental models. Additionally, while we adjusted for major known confounders, residual confounding from unmeasured factors cannot be excluded. Our genetic analysis has specific limitations. The functional consequences of the identified variants remain largely uncharacterized. Although we classified variants according to the ACMG guidelines, none have undergone functional validation through bile acid transport assays. Moreover, our targeted sequencing approach may have missed deep intronic mutations, regulatory variants, or larger structural variations that could explain phenotypes in some heterozygous cases. Finally, the clinical follow-up duration represents another limitation. While NTCPD is generally considered benign, its true long-term outcomes remain incompletely defined. Our medium-term follow-up data cannot address important questions about potential long-term sequelae, which will require dedicated longitudinal studies extending over decades.

CONCLUSION

This 5-year retrospective cohort study characterizes the dynamic genotype–phenotype relationship of NTCPD in a multi-ethnic pediatric population. The disorder manifested with marked early hypercholanemia and followed a self-limiting biochemical course that resolved with age. Genetically, the c.800C>T variant was predominant, although notable allelic heterogeneity was observed, including the identification of several previously unreported variants. Importantly, robust associations were demonstrated between specific genotypes and both TBA and vitamin E levels, which remained significant after full covariate adjustment. The results also revealed clear sex-specific phenotypic differences, namely hepatocellular stress patterns in males and nutritional metabolic imbalances in females. These results emphasize the roles of demographics and biological sex in influencing disease presentation and support the need for comprehensive genetic screening, together with a hypothesis-generating framework that may inform future study design, rather than a validated clinical strategy in NTCPD.

References
1.  Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK, Schaap FG, Oude Elferink RP, Waterham HR, Wanders RJ. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015;61:260-267.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 193]  [Cited by in RCA: 175]  [Article Influence: 15.9]  [Reference Citation Analysis (0)]
2.  Qiu JW, Deng M, Cheng Y, Atif RM, Lin WX, Guo L, Li H, Song YZ. Sodium taurocholate cotransporting polypeptide (NTCP) deficiency: Identification of a novel SLC10A1 mutation in two unrelated infants presenting with neonatal indirect hyperbilirubinemia and remarkable hypercholanemia. Oncotarget. 2017;8:106598-106607.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 33]  [Cited by in RCA: 35]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
3.  Deng M, Mao M, Guo L, Chen FP, Wen WR, Song YZ. Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency. Exp Ther Med. 2016;12:3294-3300.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 46]  [Cited by in RCA: 41]  [Article Influence: 4.1]  [Reference Citation Analysis (1)]
4.  You JY, Xiong LY, Wu MF, Fan JS, Fu QH, Qiu MH. Genetic variation features of neonatal hyperbilirubinemia caused by inherited diseases. World J Clin Pediatr. 2024;13:98462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
5.  Liu R, Chen C, Xia X, Liao Q, Wang Q, Newcombe PJ, Xu S, Chen M, Ding Y, Li X, Liao Z, Li F, Du M, Huang H, Dong R, Deng W, Wang Y, Zeng B, Pan Q, Jiang D, Zeng H, Sham P, Cao Y, Maxwell PH, Gao ZL, Peng L, Wang Y. Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine. Sci Rep. 2017;7:9214.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 45]  [Cited by in RCA: 45]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
6.  Xu JX, Lin F, Wu YH, Chen ZK, Ma YB, Yang LY. Etiology analysis for term newborns with severe hyperbilirubinemia in eastern Guangdong of China. World J Clin Cases. 2023;11:2443-2451.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 3]  [Cited by in RCA: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
7.  Ho RH, Leake BF, Roberts RL, Lee W, Kim RB. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004;279:7213-7222.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 162]  [Cited by in RCA: 143]  [Article Influence: 6.5]  [Reference Citation Analysis (1)]
8.  Wang M, Chen T, Chen R, Bi Z, Peng J, Shao Q, Li J. Neonatal jaundice caused by compound mutations of SLC10A1 and a novel UGT1A1 gene. Clin Res Hepatol Gastroenterol. 2024;48:102340.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
9.  Li H, Deng M, Guo L, Qiu JW, Lin GZ, Long XL, Xiao XM, Song YZ. Clinical and molecular characterization of four patients with NTCP deficiency from two unrelated families harboring the novel SLC10A1 variant c.595A>C (p.Ser199Arg). Mol Med Rep. 2019;20:4915-4924.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 8]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
10.  Zhou J, Yang C, Zhu W, Chen S, Zeng Y, Wang J, Zhao H, Chen Y, Lin F. Identification of Genetic Risk Factors for Neonatal Hyperbilirubinemia in Fujian Province, Southeastern China: A Case-Control Study. Biomed Res Int. 2018;2018:7803175.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 20]  [Cited by in RCA: 18]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
11.  Li H, Chen R, Lin GZ, Lin WX, Yaqub MR, Song YZ. Molecular Epidemiology of Na(+)-Taurocholate Cotransporting Polypeptide Deficiency in Guangdong Province, China: A Pilot Study by Screening for Four Prevalent Variants of the Causative Gene SLC10A1. Front Genet. 2022;13:874379.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
12.  Deng LJ, Ouyang WX, Liu R, Deng M, Qiu JW, Yaqub MR, Raza MA, Lin WX, Guo L, Li H, Chen FP, Ouyang Y, Huang YG, Huang YJ, Long XL, Huang XL, Li SJ, Song YZ. Clinical characterization of NTCP deficiency in paediatric patients : A case-control study based on SLC10A1 genotyping analysis. Liver Int. 2021;41:2720-2728.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (1)]
13.  Dawson PA. Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling. Hepatology. 2017;66:1384-1386.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 12]  [Cited by in RCA: 16]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
14.  Zong XN, Li H. Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards. PLoS One. 2013;8:e59569.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 89]  [Cited by in RCA: 140]  [Article Influence: 10.8]  [Reference Citation Analysis (0)]
15.  Sun WJ, Yu F. [Clinical analysis of two pediatric patients with sodium taurocholate cotransporting polypeptide deficiency]. Zhongguo Yiyao Daobao. 2020;17:185-188.  [PubMed]  [DOI]
16.  Sargiacomo C, El-Kehdy H, Pourcher G, Stieger B, Najimi M, Sokal E. Age-dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers. Hepatol Commun. 2018;2:693-702.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 8]  [Cited by in RCA: 12]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
17.  Song YZ. [Recent advances in the diagnosis and treatment of pediatric genetic cholestasis]. Zhonghua Shiyong Erke Linchuang Zazhi. 2017;32:561-565.  [PubMed]  [DOI]
18.  Yan YY, Wang MX, Gong JY, Liu LL, Setchell KDR, Xie XB, Wang NL, Li W, Wang JS. Abnormal Bilirubin Metabolism in Patients With Sodium Taurocholate Cotransporting Polypeptide Deficiency. J Pediatr Gastroenterol Nutr. 2020;71:e138-e141.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
19.  Du L, Zhou M, Yang J, Du M, Jiang M, Xiong L. Clinical and genetic characteristics of children with sodium taurocholate cotransporting poly-peptide deficiency. Front Pediatr. 2026;14:1784165.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (1)]
20.  Dong C, Zhang BP, Wang H, Xu H, Zhang C, Cai ZS, Wang DW, Shu SN, Huang ZH, Luo XP. Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients. Medicine (Baltimore). 2019;98:e17305.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 25]  [Cited by in RCA: 26]  [Article Influence: 3.7]  [Reference Citation Analysis (3)]
21.  Van Herpe F, Waterham HR, Adams CJ, Mannens M, Bikker H, Vaz FM, Cassiman D. NTCP deficiency and persistently raised bile salts: an adult case. J Inherit Metab Dis. 2017;40:313-315.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 25]  [Cited by in RCA: 27]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
22.  Li H, Qiu JW, Lin GZ, Deng M, Lin WX, Cheng Y, Song YZ. [Clinical and genetic analysis of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency]. Zhongguo Dang Dai Er Ke Za Zhi. 2018;20:279-284.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 8]  [Reference Citation Analysis (1)]
23.  Wang NL, Lu YL, Zhang P, Zhang MH, Gong JY, Lu Y, Xie XB, Qiu YL, Yan YY, Wu BB, Wang JS. A Specially Designed Multi-Gene Panel Facilitates Genetic Diagnosis in Children with Intrahepatic Cholestasis: Simultaneous Test of Known Large Insertions/Deletions. PLoS One. 2016;11:e0164058.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 26]  [Cited by in RCA: 35]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
24.  Zhang Q, He Z, Liu Z, Gong L. Integrated plasma and liver gas chromatography mass spectrometry and liquid chromatography mass spectrometry metabolomics to reveal physiological functions of sodium taurocholate cotransporting polypeptide (NTCP) with an Ntcp knockout mouse model. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1165:122531.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 13]  [Cited by in RCA: 12]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
25.  Mao F, Wang MX, Hou X, Zhou Z, Yan YY, Fang LJ, Tan Z, Fang WY, Liu T, He W, Li C, Xie XB, Lu SQ, Sui J, Wang F, Han J, Wang JS, Li W. NTCP Deficiency Causes Gallbladder Abnormalities in Mice and Human Beings. Cell Mol Gastroenterol Hepatol. 2021;11:831-839.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 12]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
26.  Mao F, Liu T, Hou X, Zhao H, He W, Li C, Jing Z, Sui J, Wang F, Liu X, Han J, Borchers CH, Wang JS, Li W. Increased sulfation of bile acids in mice and human subjects with sodium taurocholate cotransporting polypeptide deficiency. J Biol Chem. 2019;294:11853-11862.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 17]  [Cited by in RCA: 37]  [Article Influence: 5.3]  [Reference Citation Analysis (1)]
27.  Lin H, Qiu JW, Rauf YM, Lin GZ, Liu R, Deng LJ, Deng M, Song YZ. Sodium Taurocholate Cotransporting Polypeptide (NTCP) Deficiency Hidden Behind Citrin Deficiency in Early Infancy: A Report of Three Cases. Front Genet. 2019;10:1108.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 11]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
28.  Liu HY, Li M, Li Q. De novo mutation loci and clinical analysis in a child with sodium taurocholate cotransport polypeptide deficiency: A case report. World J Clin Cases. 2021;9:11487-11494.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
29.  Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S, de Waart DR, Tolenaars D, van der Meer JHM, Wildenberg M, Beuers U, Oude Elferink RPJ, Schinkel AH, van de Graaf SFJ. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Hepatology. 2017;66:1631-1643.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 90]  [Cited by in RCA: 125]  [Article Influence: 13.9]  [Reference Citation Analysis (1)]
30.  Chinese Society of Hepatology;  Chinese Medical Association. [Guidelines on the management of cholestasis liver diseases (2021)]. Zhonghua Gan Zang Bing Za Zhi. 2022;30:253-263.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
31.  Song YZ, Deng M. [Sodium taurocholate cotransporting polypeptide deficiency manifesting as cholestatic jaundice in early infancy: a complicated case study]. Zhongguo Dang Dai Er Ke Za Zhi. 2017;19:350-354.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 8]  [Reference Citation Analysis (0)]
32.  Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch. 2004;447:566-570.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 216]  [Cited by in RCA: 194]  [Article Influence: 8.8]  [Reference Citation Analysis (1)]
33.  Pan W, Song IS, Shin HJ, Kim MH, Choi YL, Lim SJ, Kim WY, Lee SS, Shin JG. Genetic polymorphisms in Na+-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica. 2011;41:501-510.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 78]  [Cited by in RCA: 86]  [Article Influence: 5.7]  [Reference Citation Analysis (1)]
34.  Song F, Chen Y, Chen L, Li H, Cheng X, Wu W. Association of Elevated Maternal Serum Total Bile Acids With Low Birth Weight and Intrauterine Fetal Growth Restriction. JAMA Netw Open. 2021;4:e2117409.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 31]  [Article Influence: 6.2]  [Reference Citation Analysis (0)]
35.  Chen R, Deng M, Rauf YM, Lin GZ, Qiu JW, Zhu SY, Xiao XM, Song YZ. Intrahepatic Cholestasis of Pregnancy as a Clinical Manifestation of Sodium-Taurocholate Cotransporting Polypeptide Deficiency. Tohoku J Exp Med. 2019;248:57-61.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 12]  [Cited by in RCA: 12]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
36.  Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz Ö, Fischler B, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Özen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7:830-842.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 95]  [Cited by in RCA: 146]  [Article Influence: 36.5]  [Reference Citation Analysis (0)]
37.  Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 27361]  [Cited by in RCA: 26724]  [Article Influence: 2429.5]  [Reference Citation Analysis (32)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade B, Grade B, Grade C

Novelty: Grade A, Grade B, Grade B

Creativity or innovation: Grade B, Grade B, Grade D

Scientific significance: Grade B, Grade B, Grade D

P-Reviewer: Corrales FJ, PhD, Professor, Senior Researcher, Senior Scientist, Spain; Yao Z, MD, China S-Editor: Qu XL L-Editor: A P-Editor: Yang YQ

Write to the Help Desk